Free Trial
OTCMKTS:CLPBY

Coloplast A/S (CLPBY) Stock Price, News & Analysis

$13.69
-0.08 (-0.58%)
(As of 09/18/2024 ET)

About Coloplast A/S Stock (OTCMKTS:CLPBY)

Key Stats

Today's Range
$13.50
$13.73
50-Day Range
$12.54
$14.08
52-Week Range
$9.90
$14.34
Volume
64,288 shs
Average Volume
143,491 shs
Market Capitalization
$29.57 billion
P/E Ratio
41.49
Dividend Yield
0.66%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Receive CLPBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

CLPBY Stock News Headlines

Coloplast AS ADR CLPBY
Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
See More Headlines

CLPBY Stock Analysis - Frequently Asked Questions

Coloplast A/S's stock was trading at $11.53 at the start of the year. Since then, CLPBY stock has increased by 18.7% and is now trading at $13.69.
View the best growth stocks for 2024 here
.

Coloplast A/S (OTCMKTS:CLPBY) issued its quarterly earnings results on Tuesday, August, 20th. The company reported $0.08 EPS for the quarter. The firm earned $993.49 million during the quarter. Coloplast A/S had a net margin of 18.89% and a trailing twelve-month return on equity of 31.39%.

Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/20/2024
Today
9/19/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLPBY
Previous Symbol
NASDAQ:CLPBY
Fax
N/A
Employees
15,913
Year Founded
1954

Profitability

Net Income
$685.88 million
Pretax Margin
24.01%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$0.43 per share

Miscellaneous

Outstanding Shares
2,160,000,000
Free Float
N/A
Market Cap
$29.57 billion
Optionable
Not Optionable
Beta
-0.01

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S has shown a consistent decrease in short interest, indicating potential positive market sentiment.
  • The company's stock price has been relatively stable, with a 50-day simple moving average of $12.97 and a 200-day simple moving average of $12.91.
  • Coloplast A/S reported a net margin of 19.45% and a return on equity of 36.74%, showcasing strong financial performance.
  • The company's revenue for the last reported quarter was $993.49 million, demonstrating robust business operations.
  • Equities research analysts expect Coloplast A/S to post earnings per share of 0.34 for the current year, indicating potential growth.

Coloplast A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Short interest in Coloplast A/S experienced a significant increase in July, which could signal uncertainty or negative sentiment in the market.
  • The company's price-to-earnings ratio is relatively high at 41.42, which may indicate that the stock is overvalued compared to its earnings.
  • Coloplast A/S has a price-to-earnings-growth ratio of 3.22, suggesting that the stock may be considered expensive relative to its growth prospects.
  • The company's beta of -0.02 indicates low volatility compared to the market, potentially limiting opportunities for high returns.
  • Coloplast A/S has a debt-to-equity ratio of 0.71, which could pose risks related to financial leverage and debt management.

This page (OTCMKTS:CLPBY) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners